Protocol SAKK 18/ 25 Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC Progressing on Immune Checkpoint Inhibitors: A Multicenter, Single-arm, Open-label Phase II Trial (ORIGIN2)

This Phase II clinical trial (investigates the efficacy of combining gemcitabine, a chemotherapy agent, with ivonescimab, a bispecific PD-1/VEGF antibody, in patients with advanced non-small cell lung cancer (NSCLC) who have experienced disease progression following chemoimmunotherapy (CIT). Lung cancer remains the leading cause of cancer-related death globally, and treatment options after CIT failure are limited. Gemcitabine has demonstrated immunostimulatory properties, including enhanced T-cell infiltration and reduced immunosuppressive cell populations, which may synergize with immune checkpoint inhibitors. Ivonescimab targets both PD-1 and VEGF pathways, potentially enhancing antitumor immune responses and inhibiting tumor angiogenesis. The trial aims to evaluate the objective response rate (ORR) according to RECIST v1.1 criteria. The combination therapy is expected to offer a novel and effective treatment strategy for patients with relapsed NSCLC, addressing a significant unmet medical need.

Start Date01 Mar 2026

Sponsor / Collaborator-

NCT07070466

/ Not yet recruitingPhase 2IIT

A Single-Arm, Phase II Study of Ivonescimab in Combination With FOLFOX in Advanced HER2 Negative Gastroesophageal Adenocarcinomas

This is a single arm, open-label, phase II trial investigating the combination of ivonescimab with standard FOLFOX chemotherapy in 1L therapy for HER2- GEA.

Start Date12 Dec 2025

Sponsor / Collaborator

The Massachusetts General Hospital

[+1]

NCT07057791

/ Not yet recruitingPhase 2IIT

Phase II Dose Optimization Study of Platinum/Etoposide Plus Ivonescimab (CEI) as First-Line Treatment of Extensive-Stage Small Cell Lung Cancer

Eligible untreated participants with Extensive Stage Small Cell Lung Cancer (ES-SCLC) who are ≥ 18 years of age will be randomized to receive ivonescimab 10 milligrams per kilogram (mg/kg) or ivonescimab 20 mg/kg in combination with carboplatin and etoposide.
Ivonescimab is a type of drug called a bispecific antibody. Antibodies are proteins that specifically recognize and bind to other types of proteins called antigens. Antibodies and antigens can work together to help the immune system fight cancer cells. Bispecific antibody, meaning it targets two different molecules at the same time.
Ivonescimab is a new drug that may help the immune system attack cancer cells and may also block certain pathways that cancer uses to grow and spread. This dual action of ivonescimab aims to help the immune system to fight the cancer and also disrupt tumor growth by blocking blood vessel formation that tumors use to grow.
Participants will receive induction with 4 cycles of ivonescimab (dose determined by randomization) with standard of care carboplatin and etoposide followed by maintenance therapy with ivonescimab at the same dose received during induction. Treatment will continue until disease progression, unacceptable toxicity or participant withdrawal.
The purpose of this study is to determine what dose of ivonescimab works best in combination with carboplatin and etoposide chemotherapy in ES-SCLC. We will also examine the side effects, good and bad, associated with ivonescimab.

Start Date01 Dec 2025

Sponsor / Collaborator

Summit Therapeutics, Inc.

100 Clinical Results associated with Ivonescimab

100 Translational Medicine associated with Ivonescimab

100 Patents (Medical) associated with Ivonescimab

Literatures (Medical) associated with Ivonescimab

31 Dec 2025·mAbs

Antibodies to watch in 2025

Review

Author: Kapoor, Vaishali ; Kaplon, Hélène ; Crescioli, Silvia ; Visweswaraiah, Jyothsna ; Reichert, Janice M. ; Wang, Lin

The commercial development of antibody therapeutics is a global enterprise involving thousands of biopharmaceutical firms and supporting service organizations. To date, their combined efforts have resulted in over 200 marketed antibody therapeutics and a pipeline of nearly 1,400 investigational product candidates that are undergoing evaluation in clinical studies as treatments for a wide variety of diseases. Here, we discuss key events in antibody therapeutics development that occurred during 2024 and forecast key events related to the late-stage clinical pipeline that may occur in 2025. In particular, we report on 21 antibody therapeutics granted a first approval in at least one country or region during 2024, including bispecific antibodies tarlatamab (IMDELLTRA®), zanidatamab (Ziihera®), zenocutuzumab (BIZENGRI®), odronextamab (Ordspono®), ivonescimab (®), and antibody-drug conjugate (ADC) sacituzumab tirumotecan (®). We also discuss 30 investigational antibody therapeutics for which marketing applications were undergoing review by at least one regulatory agency, as of our last update on December 9, 2024, including ADCs datopotamab deruxtecan, telisotuzumab vedotin, patritumab deruxtecan, trastuzumab botidotin, becotatug vedotin, and trastuzumab rezetecan. Of 178 antibody therapeutics we include in the late-stage pipeline, we summarize key data for 18 for which marketing applications may be submitted by the end of 2025, such as bi- or multispecific antibodies denecimig, sonelokimab, erfonrilimab, and anbenitamab. Key trends in the development and approval of antibody formats such as bispecifics and ADCs, as well as clinical-phase transition and global approval success rates for these antibody formats, are reported.

01 Aug 2025·Nature Reviews Clinical Oncology

The next generation of immunotherapies for lung cancers

Review

Author: Yang, Weiwei ; Zhang, Li ; Zhao, Hongyun ; Zhao, Shen

Immunotherapies, specifically immune-checkpoint inhibitors (ICIs) targeting PD-(L)1 or CTLA4, have revolutionized the treatment of lung cancer; however, many patients do not have a response to ICIs and most of those with an initial tumour response eventually have disease progression owing to acquired resistance. Over the past few years, numerous therapeutic strategies have been explored to address the problems of intrinsic and acquired resistance to ICIs. In 2024, regulatory approvals of the bispecific PD-1 × VEGF antibody ivonescimab for the treatment of non-small-cell lung cancer in China and the bispecific DLL3 × CD3 T cell engager tarlatamab for patients with small cell lung cancer in the USA provided clinical proof-of-concept for overcoming the challenge of ICI resistance using novel immunotherapeutic agents, thereby increasing enthusiasm for the exploration of next-generation immunotherapies for lung cancer. A large variety of immunotherapies with diverse targets and mechanisms of action are currently being tested in clinical trials involving patients with lung cancer. In this Review, we provide an overview of these emerging immunotherapies in clinical development for non-small-cell lung cancer and/or small cell lung cancer, including novel immune-checkpoint modulators, immune cell engagers, adoptive cell therapies and therapeutic cancer vaccines. We describe the designs of these agents and the mechanisms by which they might overcome resistance to the current generation of ICIs. We also discuss hurdles impeding the clinical translation of each immunotherapeutic modality and potential strategies to address these challenges, using representative examples of agents that have entered the later phases of clinical testing.

12 Jun 2025·Antibody therapeutics

A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy

Article

Author: Shen, Xiaokun ; Huang, Hao ; Wu, Ziai ; Cao, Liang ; Pan, Junfang ; Li, Zhongyuan ; Song, Zeng ; Chen, XiaoBing ; Wang, Chunyan ; Huang, Jinwen

Abstract:

Background:

Preclinical and clinical studies highlight the enhanced anticancer efficacy of combining anti-VEGF/VEGFR drugs with immune checkpoint inhibitors (ICIs). PD-L1/VEGF bispecific antibodies outperform monotherapy or combined PD-L1 inhibitors and anti-VEGF antibodies by simultaneously blocking the PD-1/PD-L1 immune pathway and VEGF-driven angiogenesis, providing a dual mechanism for superior antitumor activity.

Methods:

We developed CVL006, a novel bispecific antibody, by fusing an anti-PD-L1 VHH domain with a humanized IgG1 anti-VEGF monoclonal antibody. CVL006 retains antibody-dependent cellular cytotoxicity (ADCC) functionality. Preclinical evaluations included binding affinity and specificity assessments, dual-pathway blockade testing, and in vivo efficacy comparisons to atezolizumab and PD-1/VEGF bispecific antibody AK112 (ivonescimab).

Results:

CVL006 demonstrated high affinity and specificity for human PD-L1 and VEGF. It effectively inhibited VEGF/VEGFR signaling and the PD-L1/PD-1 axis, suppressing VEGF-induced angiogenesis and reactivating T cells. This reactivation led to increased cytokine secretion critical for immune response. In vivo studies revealed CVL006’s superior antitumor efficacy, achieving greater tumor growth inhibition and angiogenesis suppression than atezolizumab. CVL006 also outperformed AK112 in preclinical models, showcasing robust antitumor activity.

Conclusions:

CVL006 integrates immune checkpoint inhibition and tumor vascularization disruption, offering a comprehensive anticancer strategy. Its superior preclinical performance compared to atezolizumab and AK112 underscores its therapeutic potential, paving the way for further development and clinical translation.

246

News (Medical) associated with Ivonescimab

10 Sep 2025

·www.prnewswire.com

Cadonilimab(PD-1/CTLA-4) plus Pulocimab (VEGFR-2) Combination Therapy Shows Promising Results in IO-Resistant Non-Small Cell Lung Cancer in Oral Presentation at the 2025 WCLC

HONG KONG, Sept. 9, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) announced that data from a Phase Ib/II clinical study evaluating the combination of cadonilimab and pulocimab (an anti-VEGFR-2 antibody) in patients with immunotherapy (IO)-resistant NSCLC were presented in a Mini Oral session at the 2025 World Conference on Lung Cancer (WCLC). This marks the first clinical data release for cadonilimab in IO-resistant lung cancer. The cadonilimab combination therapy for advanced squamous non-small cell lung cancer (NSCLC) progressing after PD-(L)1 inhibitor treatment, has previously received Breakthrough Therapy Designation from the NMPA. The combination of cadonilimab and pulocimab also offers a potentially chemo-free option for advanced IO resistant NSCLC patients. The data presented at the 2025 WCLC demonstrated that the cadonilimab plus pulocimab regimen shows encouraging efficacy and broad clinical potential in patients with advanced or metastatic NSCLC who progressed after first-line standard immunotherapy-based treatment, offering a promising effective and safe therapeutic option for IO-resistant lung cancer patients: As of January 13, 2025, with a median follow-up of 16.7 months, the cadonilimab-based combination achieved a median overall survival (mOS) of 15.6 months and a median progression-free survival (mPFS) of 5.8 months in IO-resistant NSCLC. In the squamous NSCLC (sqNSCLC) subgroup, mOS was 16.7 months, mPFS was 7.1 months, the disease control rate (DCR) reached 96.2%, and the objective response rate (ORR) was 11.5%. In the non-squamous NSCLC (nsq-NSCLC) subgroup, mOS was 12.8 months, mPFS was 5.5 months, DCR was 95.2%, and ORR was 14.3%. Based on the promising clinical efficacy and safety data, preparation is underway for a Phase III clinical study evaluating the combination of cadonilimab and pulocimab for IO-resistant lung cancer. Additionally, ivonescimab (PD-1/VEGF), another novel bispecific antibody developed by Akeso, has shown unique efficacy and significant expansion potential in the IO-resistant NSCLC population. A registrational Phase III trial for ivonescimab has already been initiated. As first-in-class bispecific antibodies, both cadonilimab and ivonescimab are showing increasing advantages across a broadening range of disease areas. By leveraging dual-targets with synergistic mechanisms, they both address critical clinical challenges, such as limited efficacy or resistance to single-target agents like PD-1 inhibitors. This positions the bispecific antibodies as superior treatment options for patients worldwide. In recent years, immunotherapy has made significant progress in lung cancer treatment. PD-1/L1 inhibitors, either alone or with platinum-based chemotherapy, are the first-line treatment for driver-negative advanced NSCLC. However, 60%–70% of patients experience disease progression within a year. Docetaxel is the standard therapy for IO-resistant patients, but its effectiveness is limited. Improving outcomes for NSCLC patients after IO resistance remains a critical unmet need. Previous Phase III trials for IO-resistant lung cancer, including those with PD-1 inhibitors and ADCs, have not demonstrated meaningful clinical benefits. There is currently no approved standard treatment for NSCLC after resistance to IO therapies. The combination of cadonilimab and pulocimab has shown strong clinical potential in IO-resistant lung cancer, notably extending patient survival. The cadonilimab and pulocimab combination has also shown promising clinical data in other treatment-resistant cancers, including IO-resistant hepatocellular carcinoma and gastric cancer. Cadonilimab's proven efficacy for patients across all levels of PD-L1 expression, positions it as a key solution for IO-resistant cancers. This breakthrough offers a potentially new option for NSCLC patients that currently have limited treatment options after resistance to cancer immunotherapies. Forward-Looking Statement of Akeso, Inc. This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law. About Akeso Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise. For more information, please visit and follow us on Linkedin. SOURCE Akeso, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3ImmunotherapyBreakthrough TherapyClinical Result

09 Sep 2025

·www.biospace.com

BMS, BioNTech Post Geographically Consistent Mid-Stage PD-L1/VEGF Data in SCLC

iStock, boonstudio Truist Securities called pumitamig’s data on Monday “very reassuring,” given the consistency between its performance in Chinese and global patient populations. Bristol Myers Squibb and BioNTech’s investigational bispecific BNT327, also known as pumitamig, achieved high response and disease control rates in a Phase II study of small cell lung cancer, marking the first-ever global data for the anti-PD-L1/VEGF therapy. Pumitamig elicited a confirmed overall response rate (ORR) of 76.3% at the Aug. 7 data cutoff. The results, presented Monday at the 2025 World Conference on Lung Cancer, come from 38 evaluable patients who had extensive-stage small cell lung cancer. The bispecific antibody was administered alongside standard-of-care chemotherapy, achieving a 100% disease control rate. BioNTech was up 2% before the opening bell on Tuesday, while BMS was trading largely flat. In a note to investors on Monday, Truist Securities said they found this readout “very reassuring” given that it “confirmed the treatment effect seen in China” in a global patient population. BMS and BioNTech did not present geographically disaggregated figures on Monday, but a China readout in March at the 2025 European Lung Cancer Congress touted a confirmed ORR rate of 85.4% and a disease control rate of 97.9% . On Monday, BioNTech and BMS additionally reported 56.7% tumor shrinkage, with nearly 90% of participants seeing early shrinkage. Median progression-free survival was 6.8 months, while overall survival data were not yet mature at the time of the readout. In February, BioNTech launched a global Phase III study for pumitamig, dubbed ROSETTA-LUNG01, designed to evaluate the bispecific antibody plus chemotherapy as a first-line option for extensive-stage small lung cancer. That trial is expected to complete in September 2029. With ROSETTA-LUNG-01, BMS and BioNTech “are leading the race among the PD-(L)1 x VEGF bispecifics in SCLC,” Truist wrote on Monday. The analyst firm anticipates a launch in 2028, potentially unlocking a $1.4-billion revenue opportunities for the partners. By blocking both PD-L1 and VEGF, pumitamig addresses two fundamental cancer pathways: It prevents cancer cells from evading the immune response, blocking checkpoint inhibition via PD-L1, while also suppressing the formation of new blood vessels through VEGF-directed growth, that would otherwise sustain the tumor. The investigational bispecific was originally developed by Biotheus, which BioNTech acquired in November 2024 for $800 million upfront and up to $150 million in milestones. Then, in June this year, BMS put $11 billion on the line to jointly develop the asset. Monday’s readout follows a similar PD-L1/VEGF presentation by Summit Therapeutics, which on Sunday reported overall survival data for its own bispecific ivonescimab, in non-small cell lung cancer, pointing to better outcomes in Asian patients versus those in Western countries. This geographic discrepancy, as well as missing significance in overall survival outcomes, makes ivonescimab’s regulatory prospects “uncertain,” Truist wrote in a separate note on Monday.

Clinical ResultAcquisitionPhase 3Phase 2ASCO

08 Sep 2025

·firstwordpharma.com

WCLC25: Second readout for BioNTech, BMS's PD-L1/VEGF-A underwhelms in SCLC

Newly partnered BioNTech and Bristol Myers Squibb presented fresh mid-stage data on their PD-L1/VEGF bispecific pumitamig (formerly BNT327) at the World Conference on Lung Cancer (WCLC) on Monday, but the seemingly positive results in patients with extensive-stage small-cell lung cancer (ES-SCLC) failed to impress investors, sending BioNTech's shares down about 8%. Bispecific rival Summit Therapeutics also couldn't catch a break at WCLC. The company's stock fell more than 23% on Monday after new survival results in non–small-cell lung cancer (NSCLC) for its PD-1/VEGF–targeting antibody ivonescimab were muddled by data disparities between the Asian versus non-Asian subgroups.Both compounds have been hyped as potential challengers to Merck & Co.'s blockbuster PD-1 inhibitor, Keytruda (pembrolizumab) — which helped BioNTech attract BMS as a partner. In June, the pharma paid $1.5 billion upfront to co-develop pumitamig, with BioNTech eligible to receive about $11 billion more. As for Summit, AstraZeneca is reportedly interested in buying rights to ivonescimab for $15 billion, but nothing has yet come of the July rumours (see – Spotlight On: BMS's bispecific deal with BioNTech — The key takeaways).Survival, response resultsCohort 1 of the global Phase II trial randomised 43 patients with ES-SCLC to receive either 20 mg/kg or 30 mg/kg pumitamig every three weeks, plus chemotherapy. At the August 7 data cut-off, 38 patients had evaluable results. The market reaction may have been due to divergent results for the two dose levels. While patients taking the 20-mg/kg dose had a superior confirmed overall response rate (ORR) than the 30 mg/kg arm's (85% versus 66.7%), the high-dose group had a longer progression-free survival (PFS) of 7 months compared with 6.3 months for the low-dose arm. Combined results across both dosing groups showed a confirmed ORR of 76.3%, PFS of 6.8 months, and disease control rate (DCR) of 100%. Median overall survival (OS) is not yet mature. "These are the first-ever data in a global population in advanced small-cell lung cancer for a PD-(L)1 x VEGF bispecific antibody, supporting a possible new standard of care for patients with extensive-stage small-cell lung cancer," said Bryan Campbell, head of Program Leadership, Hematology, Oncology, Cell Therapy at Bristol Myers Squibb.BioNTech said the findings were in-line with an earlier Phase II study conducted in China that evaluated only the 30-mg/kg dose of pumitamig. The results, presented at the European Lung Cancer Congress (ELCC) in March, showed that in 48 ES-SCLC patients, the bispecific-chemotherapy combination led to an ORR of 85.4%, median PFS of 6.9 months, and a DCR of 97.9%. On the safety front, the partners said pumitamig plus chemotherapy had a "manageable" profile, with a discontinuation rate of 14%. One patient who received the low dose and five taking the high dose experienced a Grade ≥3 pumitamig-related treatment-emergent adverse event including hypertension, decreased platelet count, haemoptysis, proteinuria and pulmonary embolism. BioNTech has already launched the pivotal ROSETTA clinical programme, which is evaluating pumitamig plus chemotherapy in Phase III trials for NSCLC, SCLC, and triple-negative breast cancer (see – Spotlight On: Combos key to BioNTech’s PD-L1/VEGF bispecific strategy).While investor focus seems to be squarely on pumitamig, BioNTech's HER2-targeting antibody-drug conjugate trastuzumab pamirtecan (BNT323/DB-1303) may be the first of its oncology programmes to win regulatory approval. For further analysis, see Vital Signs: BioNTech nears its validation for big oncology bets.

Clinical ResultPhase 3Phase 2Cell TherapyADC

100 Deals associated with Ivonescimab

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
PD-L1 positive Non-Small Cell Lung Cancer	China	Akeso-Sino Pharma Co., Ltd.	22 Apr 2025
EGFR positive Non-squamous non-small cell lung cancer	China	Akeso-Sino Pharma Co., Ltd.	21 May 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Lung Non-Small Cell Squamous Carcinoma	NDA/BLA	China	Akeso Pharmaceuticals, Inc.	25 Jul 2025
Advanced Lung Non-Small Cell Squamous Carcinoma	NDA/BLA	China	Akeso-Sino Pharma Co., Ltd.	25 Jul 2025
Non-Small Cell Lung Cancer	Phase 3	China	Akeso Biopharma Co., Ltd.	30 Jun 2025
Advanced Lung Non-Small Cell Carcinoma	Phase 3	-	Akeso Biopharma Co., Ltd.	01 Jun 2025
Small Cell Lung Cancer	Phase 3	China	Akeso Biopharma Co., Ltd.	29 May 2025
Small cell lung cancer limited stage	Phase 3	China	Akeso Biopharma Co., Ltd.	29 May 2025
Metastatic Pancreatic Cancer	Phase 3	China	Akeso Biopharma Co., Ltd.	14 May 2025
Adenocarcinoma of large intestine	Phase 3	China	Akeso Biopharma Co., Ltd.	09 May 2025
Metastatic Colorectal Carcinoma	Phase 3	China	Akeso Biopharma Co., Ltd.	09 May 2025
PD-L1 negative Triple Negative Breast Cancer	Phase 3	China	Akeso Biopharma Co., Ltd.	07 Feb 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05184712 (HARMONi-A, NEWS) Manual	Phase 3	EGFR-mutated non-small Cell Lung Cancer EGFR-mutated	-	ivonescimab + chemotherapy	xkxaottjtw(jctdipctza) = the Phase III HARMONi-A trial met its OS goal, showing that ivonescimab. szawhgbmpp (fuoedkkods ) Met	Positive	26 Aug 2025
				placebo + chemotherapy
NCT06396065 (HARMONi, NEWS 1 \| NEWS 2) Manual	Phase 3	Non-squamous non-small cell lung cancer \| EGFR positive Neoplasms Second line EGFR Mutation	-	ivonescimab +化疗	agzkrzvhdm(dpcilojciv): 0.52 (95.0% CI, 0.41 - 0.66), P-Value = <0.00001 View more	Positive	30 May 2025
				化疗
NCT06375486 (ASCO2025)	Phase 2	Unresectable Hepatocellular Carcinoma First line HBV infection \| portal vein tumor thrombosis \| extrahepatic spread	27	Ivonescimab + HAIC	btiixvoakn(cwpcxacuec) = lpfwlqvnqd bnzorztufe (mqyhtucule ) View more	Positive	30 May 2025
NCT05899608 (HARMONi-3, ASCO2025)	Phase 3	metastatic non-small cell lung cancer First line \| Maintenance	1,080	Ivonescimab plus chemotherapy	swvwktxbdy(evrdadjkml) = jmqonvzgjf iwfnrzhrre (oasmkirisz ) View more	Positive	30 May 2025
				Pembrolizumab plus chemotherapy	swvwktxbdy(evrdadjkml) = xeudvelqvh iwfnrzhrre (oasmkirisz ) View more
NCT05840016 (AK112-306 \| HARMONi-6, Company_Website) Manual	Phase 3	Squamous non-small cell lung cancer First line	532	ivonescimab + chemotherapy	duodrfufhr(awuyzbquan) = in the intention-to-treat (ITT) population, ivonescimab plus chemotherapy decisively beat tislelizumab plus chemotherapy in terms of progression-free survival (PFS). wwutbgxyrp (kzzfrqcwle ) Met View more	Superior	22 Apr 2025
				tislelizumab + chemotherapy
NEWS Manual	Phase 2	Resectable Lung Non-Small Cell Carcinoma Neoadjuvant	-	伊沃西单抗 20 mg/kg (队列1)	ivjvclitrl(bziurymokr) = jgwewpaznw ujjhngjmzq (bpasipmevn ) View more	Positive	20 Jan 2025
				伊沃西单抗 20 mg/kg或30 mg/kg + 联合化疗 (队列2)	ivjvclitrl(bziurymokr) = arfzftbxcs ujjhngjmzq (bpasipmevn ) View more
NCT05184712 (HARMONi-A, ESMO_IO2024 \| NEWS) Manual	Phase 3	EGFR-mutated non-small Cell Lung Cancer EGFR Mutation	322	Ivonescimab (Ivo) + Pemetrexed/Carboplatin	rbmpoewnyq(akfmznqjwu) = yfjhpqigds xmlmbkhgrc (erhnkuwdyn ) View more	Positive	12 Dec 2024
				Placebo + Pemetrexed/Carboplatin	rbmpoewnyq(akfmznqjwu) = jshiytwdcv xmlmbkhgrc (erhnkuwdyn ) View more
NCT05227664 (SABCS2024) Manual	Phase 2	Triple Negative Breast Cancer First line	30	Ivonescimab + Paclitaxel/Nab-paclitaxel	qogmgretcs(conwvrvsox) = aejfrrxflb tbllvdwkkm (quoqsrwytv ) View more	Positive	26 Nov 2024
				Ivonescimab + Paclitaxel/Nab-paclitaxel (PD-L1 CPS ≥10)	qogmgretcs(conwvrvsox) = cdochxngxl tbllvdwkkm (quoqsrwytv ) View more
NCT05227664 (ESMO2024) Manual	Phase 2	Triple Negative Breast Cancer First line HER2 Negative \| ER Negative \| PR Negative	30	Ivonescimab 20Paclitaxel + Pnab-paclitaxelg/m2	qvfviybatw(yjrazzjfds) = jvntmvhjza dicjfafquj (kjcxqhmqul ) View more	Positive	16 Sep 2024
				Ivonescimab 20Paclitaxel + Nnab-paclitaxel100 mg/m2	qvfviybatw(yjrazzjfds) = uenwglwxma dicjfafquj (kjcxqhmqul ) View more
NCT05229497 (ESMO2024) Manual	Phase 2	Squamous Cell Carcinoma of Head and Neck First line PD-L1 Positive	30	Ivonescimab monotherapy	ojlvtbyvhk(bksrqpwmjm) = svqmewrsjm bglavizpfk (klknxfndmz ) View more	Positive	14 Sep 2024
				Ivonescimab plus ligufalimab	ojlvtbyvhk(bksrqpwmjm) = xxpzivxvan bglavizpfk (klknxfndmz ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ivonescimab

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation